Get the Stockscreener App
34.12
2.12%
-0.78
Bridgebio Pharma Inc stock is traded at $34.12, with a volume of 793.45K.
It is down -2.12% in the last 24 hours and up +10.09% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$34.90
Open:
$34.54
24h Volume:
793.45K
Relative Volume:
0.29
Market Cap:
$6.49B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-14.16
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
-5.77%
1M Performance:
+10.09%
6M Performance:
+18.86%
1Y Performance:
-4.13%
1-Day Range:
$33.86
$35.00
1-Week Range:
$32.50
$35.46
52-Week Range:
$21.62
$39.47
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
34.10 | 6.49B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.20 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.02 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.42 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.24 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.59 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
Leerink Partnrs Has Optimistic Outlook of BBIO Q1 Earnings - MarketBeat
Y Intercept Hong Kong Ltd Increases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
What is Leerink Partnrs' Forecast for BBIO Q3 Earnings? - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownTime to Sell? - MarketBeat
Q1 Earnings Estimate for BBIO Issued By Leerink Partnrs - MarketBeat
Brian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares - MarketBeat
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - Citeline News & Insights
BridgeBio Pharma Strengthens Financial Position with Note Issuance - TipRanks
BridgeBio Pharma Issues $575 Million Of 1.75% Convertible Senior Notes Due 2031 - Marketscreener.com
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - MedCity News
BridgeBio Pharma, NetApp, Talen Energy - TradingView
Raymond James resumes coverage on BridgeBio with 'outperform' on heart drug optimism - TradingView
BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive
BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go public - The Business Journals
BridgeBio spinout to go public in SPAC deal (HLXB:NASDAQ) - Seeking Alpha
Helix Acquisition to Merge With BridgeBio Oncology Therapeutics -February 28, 2025 at 09:37 am EST - Marketscreener.com
$450M Deal Powers New Cancer-Fighting Biotech: What's Inside BridgeBio's Oncology SPAC Merger? - StockTitan
BridgeBio price target raised to $46 from $45 at BofA - TipRanks
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsBBIO - ACCESS Newswire
BridgeBio prices offering of $500 million convertible senior notes due 2031 - MSN
BridgeBio Pharma CFO Brian Stephenson sells $282,114 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $2.52 million in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Bayer Execs Roth And Eckhardt On Current And Future Pharma Growth - Citeline News & Insights
BridgeBio Pharma CFO Brian Stephenson sells $282,114 in stock - Investing.com India
BridgeBio Pharma CEO Neil Kumar sells $2.52 million in stock - Investing.com India
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
BridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Principal Financial Group Inc. Reduces Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HealthInvest Partners AB Buys 49,600 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Latham & Watkins Advises on BridgeBio’s US$500 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
BridgeBio up after $500 mln convertible debt deal priced - TradingView
BridgeBio Pharma Prices $500 Million Convertible Senior Notes Offering -February 26, 2025 at 05:59 am EST - Marketscreener.com
BridgeBio Pharma, Inc. Prices $500 Million Convertible Senior Notes Offering to Lower Debt and Enhance Financial Flexibility - Nasdaq
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt - GlobeNewswire
How BridgeBio's $500M Debt Refinancing Could Strengthen Its Financial Future - StockTitan
When the Price of (BBIO) Talks, People Listen - Stock Traders Daily
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $52.00 at Scotiabank - MarketBeat
BridgeBio announces offering of convertible senior notes to refinance debt - MSN
BridgeBio's SWOT analysis: genetic disease stock poised for growth - Investing.com India
BridgeBio’s SWOT analysis: genetic disease stock poised for growth - Investing.com
Insider Sell-Offs Shake BridgeBio Pharma Stocks - TipRanks
BridgeBio Pharma (NASDAQ:BBIO) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
BridgeBio announces $500 million convertible notes offering By Investing.com - Investing.com Nigeria
BridgeBio Pharma To Offer $500 Million Convertible Senior Notes Due 2031 - TradingView
BridgeBio announces $500 million convertible notes offering - Investing.com India
BridgeBio stock falls on convertible notes offering By Investing.com - Investing.com South Africa
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | CFO and Treasurer |
Feb 25 '25 |
Sale |
33.19 |
8,500 |
282,115 |
102,464 |
| Kumar Neil | Chief Executive Officer |
Feb 25 '25 |
Sale |
33.57 |
75,000 |
2,517,971 |
5,023,447 |
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):